Inside the KLOW Stack: The Four Peptides

In plain English

The KLOW stack is four peptides in one vial. KPV is the anti-inflammatory arm — a three-amino-acid fragment that dials down inflammation in gut and immune cells. GHK-Cu is the skin and matrix arm — the copper-chelated tripeptide that reshapes collagen and gene expression, and makes up most of the vial by weight. BPC-157 is the angiogenic and tendon-repair arm — it tells cells to grow new blood vessels and repairs tendons in rat studies. TB-500 is the wound-closure arm — a fragment of a protein that helps cells migrate to close wounds. They were designed to cover four separate steps of repair. Whether they actually work better together than any one alone is a question no study has answered.

KPV — the anti-inflammatory arm

KPV (Lys-Pro-Val) is the C-terminal tripeptide (residues 11-13) of alpha-MSH (alpha-melanocyte-stimulating hormone, a 13-residue regulatory peptide). Molecular weight: 342.44 Da. CAS: 67727-97-3.

Role in the blend: anti-inflammatory. Its studied mechanism is inhibition of NF-kappaB nuclear import — blocking the transcription factor (NF-kappaB) that switches on inflammatory genes — and suppression of MAPK inflammatory signaling, with downstream reductions in TNF-alpha, IL-6, IL-1beta and IL-8 ^[3].

Uptake: KPV is a substrate of PepT1 (SLC15A1), the intestinal di/tripeptide transporter that is upregulated in inflamed gut epithelium, with a Km of approximately 160 micromolar. This transporter-mediated uptake is the mechanistic basis for its gut-targeted anti-inflammatory effect ^[3].

Evidence level: human intestinal cell cultures and mouse colitis models. No approved human indication. 10 mg in the canonical 80 mg KLOW vial.

GHK-Cu — the skin-matrix arm

GHK-Cu (Gly-His-Lys copper(II) complex, Copper Tripeptide-1) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. Molecular weight: 402.92 Da. CAS: 89030-95-5.

Role in the blend: skin-matrix and gene-expression modulator, and the mass-dominant component (50 of 80 mg, 62.5% by mass). At low-nanomolar concentrations in fibroblasts, GHK modulates approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold ^[5]. The strongest signals are on extracellular-matrix remodeling, antioxidant defense, DNA repair and anti-inflammatory programs. It stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin ^[4], and supplies copper for lysyl oxidase — the copper-dependent enzyme that crosslinks collagen and elastin.

Plasma GHK declines from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 ^[4], a decline associated with age-related shifts in fibroblast behavior. Topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid in a placebo-controlled comparison ^[4].

Evidence level: extensive topical human cosmetic data; in vitro gene-expression studies; one penetration study quantifying topical copper delivery ^[8]; 2024–2025 mechanistic and formulation reviews ^[11][12]. No systemic human indication approved.

BPC-157 — the angiogenic repair arm

BPC-157 (Body Protection Compound 157, pentadecapeptide, PL 14736) is a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a protein identified in human gastric juice. Molecular weight: 1419.53 Da. CAS: 137525-51-0.

Role in the blend: angiogenic and tissue-repair arm. Primary mechanism: VEGFR2/PI3K/Akt/eNOS activation — driving new blood-vessel formation from existing vessels. Also upregulates the growth-hormone receptor in tendon fibroblasts and modulates the nitric-oxide system in a manner partly resistant to L-NAME ^[2].

Key result: accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and histological measures at doses from 10 μg down to 10 pg per rat once daily IP ^[2].

Evidence level: extensive rodent model data; one 2025 two-person IV safety pilot ^[6]; one 2024 uncontrolled interstitial cystitis pilot ^[13]. FDA 503A category 2. 10 mg in the canonical KLOW vial.

TB-500 — the cytoskeletal wound-closure arm

TB-500 (Ac-LKKTETQ) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of thymosin beta-4 (Tbeta4, the full-length 43-amino-acid native protein). Molecular weight: 889.02 Da. No CAS number issued for the fragment.

Role in the blend: cytoskeletal and wound-closure arm. The LKKTET motif sequesters G-actin (monomeric actin), holding it in reserve for cell migration and re-epithelialization. Full-length thymosin beta-4 additionally activates integrin-linked kinase (ILK) and mobilizes epicardial progenitors — activities not demonstrated for the TB-500 fragment ^[1].

Key result: topical or IP thymosin beta-4 (full-length) increased re-epithelialization by 42% at 4 days and 61% at 7 days in a rat wound model, increased contraction (≥11% at day 7) and stimulated keratinocyte migration at as little as 10 pg ^[1]. These findings apply to the native full-length protein.

Critical compliance note: thymosin beta-4 / TB-500 is listed on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition ^[7]. 10 mg in the canonical KLOW vial.

Evidence level: extensive rodent and ex vivo data for full-length Tbeta4; limited fragment-specific data.

KLOW vs GLOW

KLOW and GLOW are related but distinct research blends. GLOW contains GHK-Cu, BPC-157, and TB-500 — three of the four KLOW components — but does not include KPV. The addition of KPV is the structural difference that defines KLOW versus GLOW.

In research-use community accounts, the KPV arm is often credited with giving KLOW a more pronounced anti-inflammatory character than GLOW — a perceived difference in the 'feel' of the two stacks, attributed to KPV's NF-kappaB-suppressive effect. This is anecdotal community comparison, not a head-to-head controlled study.

KLOW is not WOLVERINE, which is a separate research blend with a different composition. These three blends are distinct research formulations, each with its own component profile and its own absent combination trial.

The pharmacokinetic mismatch

A co-formulated vial cannot overcome the pharmacokinetic reality: the four KLOW peptides clear at very different rates. The tripeptides KPV and GHK-Cu are small (342 and 402 Da respectively) and clear quickly. BPC-157's formal rat-plasma half-life from the published PK study is under approximately 30 minutes. The TB-500 fragment behaves differently from full-length thymosin beta-4 (43 amino acids), and its pharmacokinetics have not been formally characterized.

The consequence: a single co-formulated dose will not maintain all four components at meaningful concentrations in any target tissue simultaneously. Whether sequential rather than simultaneous exposure achieves the desired four-arm effect — and whether the pharmacokinetics are even relevant to the claimed mechanisms — is not known. No study has addressed this question for KLOW.